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Vascular anomalies of the central nervous system (CNS) in
children are diverse in nature and can have markedly differ-
ent outcomes. In general, lesions that do not have direct
arterial-to-venous shunts are usually associatedwith a lower
likelihood of spontaneous hemorrhage and a more benign
natural history. For example, developmental venous anoma-
lies consist of a prominent draining vein, often in a deep
location, which do not cause intracerebral hemorrhage and
do not usually require further investigation or treatment.1
Cavernous malformations—which are often associated with
developmental venous anomalies—contain thin-walled vas-
cular channels but are not visible on traditional catheter
angiograms and often have an indolent course.2,3 In this
review, we will discuss the etiologies, epidemiology, natural
history, and genetic risk factors of three high-flow vascular
malformations seen in children: brain arteriovenous malfor-
mations (AVMs), dural arteriovenous fistulas (DAVFs), and
vein of Galen malformations (VoGMs). These malformations
often require individualized treatment utilizing multiple
modalities over a longer period of time. We will not sepa-
rately discuss a fourth type of high-flow intracranial AVF, the
pial nongalenic AVF, which has been reviewed elsewhere.4
Arteriovenous Malformations
Brain AVMs are fragile clusters of blood vessels composed of
abnormal connections between arteries and veins without an
intervening capillary bed, resulting in a structure defined as a
nidus.5 The lack of resistance within the nidus leads to high-
flow shunting of blood between arterial and venous circula-
tions. The increased pressurewithin abnormal vessels—which
includes the nidus, feeding artery aneurysms, and outflow
venous varices—can lead to spontaneous intracerebral hemor-
rhage. A greater proportion of children as compared with
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Abstract Children can have a variety of intracranial vascular anomalies ranging from small and
incidental with no clinical consequences to complex lesions that can cause substantial
neurologic deficits, heart failure, or profoundly affect development. In contrast to high-
flow lesions with direct arterial-to-venous shunts, low-flow lesions such as cavernous
malformations are associated with a lower likelihood of substantial hemorrhage, and a
more benign course. Management of vascular anomalies in children has to incorporate
an understanding of how treatment strategies may affect the normal development of
the central nervous system. In this review, we discuss the etiologies, epidemiology,
natural history, and genetic risk factors of three high-flow vascular malformations seen
in children: brain arteriovenous malformations, intracranial dural arteriovenous fistu-
las, and vein of Galen malformations.
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adults present as the result of rupture, and AVMs are the
leading cause of nontraumatic intracerebral hemorrhage in
children.6–10 In patients presenting with spontaneous hemor-
rhage, treatment is usually considered, since the strongest
predictor of a future AVM hemorrhage is a prior hemorrhage.
In those patients whose AVM is identified without a prior
hemorrhage, the annual likelihood of hemorrhage is low, but
the cumulative risk over a child’s lifetime is likely to be
substantial, and treatment is often favored if the risks are
acceptable. Available treatment modalities include surgical
resection, embolization, and stereotactic radiotherapy, either
as single or multimodal therapy. While a prior clinical trial
evaluatedoutcomes for treatmentofAVMs inadults, this study
did not include children.11 Because no prospective clinical
trials have evaluated the management of pediatric AVMs, the
selection of an appropriate treatment strategy and timing of
treatment is guided by empiric evidence and extrapolation
from data obtained from adult patients.
Etiology and Genetics
Less than 5% of AVMs occur as part of a clinical syndromewith
an autosomal dominant pattern of inheritance. Examples of
syndromes associatedwith AVM formation includehereditary
hemorrhagic telangiectasia (HHT) which results from muta-
tions inENG,ACVRL, andSMADfamilymember4 (SMAD4), and
capillary malformation-arteriovenous malformation (CM-
AVM) syndrome which results from mutations in Ras GTPase
activating protein (RASA1) and Ephrin type-B receptor 4
(EPHB4) genes.12,13 More recently, somatic activating muta-
tions have been identified in the KRAS proto-oncogene, and
this alteration may account for a majority of nonsyndromic
AVMs.14 Mutations in other genes, such as BRAF, SMAD9, and
BMP9, have also been identified, but whether these directly
result in AVM formation is not known.15–17
Historically, AVMs were thought to be congenital lesions
arising from abnormal connections between arteries and
veins that formed in utero. More recent works in rodent
models and longitudinal clinical series have suggested that
AVMs may be acquired after birth. Rodent models have
supported a two-hit hypothesis. First, mutations in trans-
forming growth factor-β (TGF-β) receptor genes that cause
HHT (associated OMIM numbers:131195, 187300, 601284,
600376, 600973, 175050)—such as activin-like kinase 1
(ALK1 or ACVRL) or endoglin (ENG)—render the animal
susceptible. Second, activation of brain angiogenesis via
either an injury and subsequent wound healing or over-
expression of vascular endothelial growth factor (VEGF)
triggers AVM formation.13,18–21 Targeting critical proteins
in this molecular cascade, including ALK1, endoglin, and
VEGF, has been explored using novel therapeutic agents.22
Bevacizumab, for example, has been used inmousemodels of
brain AVMs to reduce growth of intracranial lesions.23
Whether these molecular changes ultimately lead to
formation of an anomalous direct arterial-venous connec-
tion or progressive dilatation of microvascular beds remains
controversial, but both mechanisms are described in rodent
models.20,24,25 Many of these abnormalities are thought to
arise within the endothelium,19,26 but several other studies
suggest that other cell types, such as pericytes, play an
important role.21,27,28 The use of thalidomide, which
increases platelet-derived growth factor receptor-β and pro-
motes pericyte recruitment, decreases the risk of hemor-
rhage from brain AVMs in a mouse model.28
Epidemiology and Natural History
The prevalence of brain AVMs is estimated to be 10 to 18 per
100,000 people,29,30 and although the annual rate of hemor-
rhage is estimated to be between 2 and 4%, AVMs are the
leading cause of nontraumatic intracranial hemorrhage in
children.6–9,11,31–36 However, for lesions that previously bled
andwere not treated, the risk of rehemorrhage was estimated
to be 11.5% per patient-year.37 For AVMs harboring multiple
high-risk features (such as prior hemorrhage, deep venous
drainage, anddeepAVMlocation), theannual hemorrhage rate
may be as high as 34.4%.33 Recent studies in children and
adolescents have reported an annual rate of hemorrhage from
0.9 to 6.3%.6,7 However, all hemorrhage estimates are inher-
ently limited by selection bias, as lesionswith a low treatment
risk or high hemorrhage risk are more often selected for
treatment. Features such as a deep location, purely deep
venous drainage, associated aneurysms, or prior bleeding
may substantially increase the risk of bleeding.33 Specific
angioarchitectural features associated with higher risk of
hemorrhage, such as feeding artery aneurysms and outflow
venous ectasia, appear to be more common in older patients
and are underrepresented in children.10 Following AVM hem-
orrhage, neurologic disability andmortality occur in 20 to 30%
and 10% of patients, respectively.30 A randomized controlled
trial (e.g., A Randomized Trial of Unruptured Brain AVMs
[ARUBA]) and prospective registry study (e.g., the Scottish
Audit of Intracranial Vascular Malformations [SAIVM]) both
suggested that the risk of stroke or death associated with
treatment may exceed potential risks of bleeding with obser-
vation of an unruptured AVM.11,38 It should be noted that
children and adolescents were excluded from these studies. In
addition, the mean follow-up period for ARUBA was 3 years,
which underestimates the cumulative hemorrhage risk in a
young patient whose life expectancy is measured in decades.
Finally, there are some data which show that bleeding risk
increases with age,33,34,39,40 and for this reason many centers
favor treatment of AVMs in children and adolescents.
Clinical Presentation
Neurologic symptoms can result fromhemorrhage, compres-
sion of eloquent neurologic structures, and/or alteration in
blood flow dynamics. A greater proportion of children pres-
ent as the result of spontaneous hemorrhage.6–9 The exact
pattern of neurologic symptoms is dependent on lesion
location and size of the hemorrhage, but may include head-
ache, seizure, weakness, numbness, visual disturbances, or
cranial neuropathies. With hemorrhage, neurologic findings
are often sudden in onset and may be accompanied by
clinical signs such as severe headache, nausea, vomiting,
and alterations inmental status caused by raised intracranial
pressure. Less often, subacute or chronic progressive neuro-
logic abnormalities may result from either compression or
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ischemia arising from alterations in regional cerebral hemo-
dynamics—the so-called vascular steal phenomenon (al-
though this may actually represent local venous
hypertension).41 In two separate reports which focused on
children with AVMs, presenting symptoms included hemor-
rhage (57.5–58%), seizures (12–20%), progressive neurologic
deficits (11%), headache (5–14%), cardiac failure (5%), and
incidental (6–7.5%).42,43
Diagnostic Imaging
For patients presenting with acute focal neurologic deficits
or clinical concerns for raised intracranial pressure, a rapid
magnetic resonance imaging (MRI) study or a low-dose
computed tomography (CT) scan should be obtained. If an
underlying vascular malformation is suspected, the initial
MRI or CT scan should be accompanied with brain vascular
imaging such as MR angiography or CT angiography. In
general, CT-based imaging should be avoided to minimize
radiation exposure. If the initial workup is suggestive of an
AVM, catheter-based digital subtraction cerebral angiogra-
phy (DSA) is essential and provides important additional
information required for appropriate decision making. DSA
allows comprehensive assessment of feeding arterial supply,
structure of the nidus, venous drainage, and evaluation for
high-risk features including flow-related or intranidal aneur-
ysms and venous varices. If surgery is anticipated, then a
diagnostic study is often performed in conjunction with
therapeutic embolization of accessible feeding arteries. A
preoperative neuronavigation MRI with diffusion tensor
imaging, and/or functional imaging obtained prior to sur-
gery, may facilitate selection of safer surgical routes, and
thereby reduce the likelihood of causing new postoperative
deficits.44,45
Treatment Selection
In patients presenting with a large intracerebral hemorrhage
and symptoms from mass effect, an urgent decompressive
craniectomy should be performed without delay. In some
patients, management of elevated intracranial pressure is a
priority andmay delay definitive treatment of the underlying
AVM. Once a patient is clinically stable, additional inves-
tigations can be performed prior to treatment of the AVM.
Deferring definitive treatment should be balanced against
the risk of rehemorrhage. In patients with very large AVMs,
definitive treatment may not be possible.
For most AVMs, the treatment options include surgical
resection, endovascular embolization, stereotactic radiosur-
gery, or a combination of these modalities.37 Selection of the
appropriate treatment modality and optimal timing of inter-
vention remains controversial.11,38Although generalizations
can be made used for different groups of AVMs, each indi-
vidual AVM has unique features, and comprehensive treat-
ment planning is best performed in high-volume centers
with multidisciplinary teams.
Surgical Resection
In clinical series, complete surgical resection is often associat-
ed with earlier and higher obliteration rates in comparison to
endovascular embolization and/or stereotactic radiosur-
gery.6,43,46–48 However, achieving a complete resection must
bebalanced against thepredictedmorbidityof that procedure.
Although surgical resection for AVMs is better tolerated in
children andadolescents than in adults,47 a careful assessment
of thecomplexityof theAVMisa crucialfirst stepand isusually
accomplished with the use of grading systems. The Spetzler-
Martin (SM) system uses lesion size (<3 cm, 3–6 cm, >6 cm),
venous drainage pattern (deep or superficial), and location
(eloquencevs. noneloquence) to stratify AVMs intofive grades.
The Lawton-Young Supplementary (Supp) grading system
adds age (<20, 20–40, and >40), nidus morphology (compact
vs. diffuse), and hemorrhage status to the SM system.49–51
AVMs that are both accessible and have combined SM-Supp
scoresof6aregenerally thought tohavea risk–benefit profile
favorable for surgery. Thosewith a SM-Supp score7 are often
considered for other treatments such as stereotactic radiosur-
gery (SRS).49,50 The details for AVM surgery have been previ-
ously described,52 and reported surgical obliteration rates
often exceed 90% in clinical series.6,47,53
Endovascular Embolization
Endovascular embolization, if feasible and safe, is a necessary
preoperative adjunct to reduce blood flow and/or secure high-
risk features, such as flow-related and/or intranidal aneurysms,
mitigate blood loss with surgery, or potentially reduce risk
of hemorrhage in the latency period of radiosurgery.54,55
Numerous endovascular embolization tools are available, in-
cluding n-butyl cyanoacrylate, Onyx, and detachable coils.56–60
Cure with embolization as a sole treatment modality has been
reported,61,62 althoughoverall cure rates are generally lowsince
most AVMs have multiple feeding arteries and not all can be
reached safely, even with modern superselective cathe-
ters.54,55,63 Partial embolization of an AVM nidus is associated
with increased risk of hemorrhage,6,46 and therefore is not
generally favored as an isolated treatment option. Newer trans-
venous embolization approaches may increase the subset of
AVMs potentially cured with embolization alone.61,64
Stereotactic Radiosurgery
Stereotactic radiosurgery utilizes external ionizing radiation
sources and a three-dimensional coordinate system to deliver
a high radiation dose to a selected target with very high
accuracy. Stereotactic radiosurgery is an excellent option for
the treatment of AVMs in deep or eloquent brain regions,
locations which would have a high likelihood of morbidity if
surgical resection was chosen. The morbidity of radiosurgical
treatment is low. However, in the short term, the seizure
threshold can be reduced, headaches can increase, and occa-
sionally focal neurological deficits develop.When these symp-
toms occur, they typically begin months after treatment and
can last for months, but usually resolve completely with time.
Obliteration rates increase with small lesions and higher
marginal dose.65 In our center, a prescription marginal dose
of 18 Gy is associated with an obliteration rate of approxi-
mately 52%.65Otherswho treat with amarginal dose of20or
22 Gy have reported obliteration rates ranging from 63 to
71%.66,67 Obliteration, however, takes several years and
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patients are at risk for hemorrhage during the latent
period.7,66,68 With higher radiation doses or volumes
treated, risks for symptomatic radiation-induced changes
increases,7,68,69 and a greater incidence is reported for AVMs
in deeper anatomic locations, such as the brainstem, striatum,
or thalamus.69 With greater nidus volumes (>8–10 cm3),
volume-staged radiosurgery may be performed, involving
multiple sessions in which roughly 8 to 10 cm3 of the AVM
nidus are treated in each session in 3- to 6-month inter-
vals.70–72AnnualMRIs and catheter angiographyat 36months
after treatment are usually obtained to monitor treatment
response. Thecure rates for largeAVMsaregenerally lower, but
radiosurgerymay lead to a decrease of the grade of a subset of
AVMs, which then may facilitate definitive surgical resection
with a reduced risk.70►Fig. 1 provides a case example of this
technique.
Dural Arteriovenous Fistulas
Dural arteriovenous fistulas (DAVFs) are rare high-flow
vascular lesionswith an aberrant, direct connection between
a dural artery and either a venous sinus or cortical vein. Some
DAVFs have only a single arteriovenous shunt, while others
have numerous connections. These lesions make up approx-
imately 5 to 10% of pediatric intracranial arteriovenous
shunts and tend to be associatedwith a higher riskof rupture
compared with adult patients.73–75 Treatment of DAVFs in
pediatric patients has been associated with poor outcomes,
and these lesions remain a therapeutic challenge.76
Etiology and Genetics
The pathogenesis of DAVFs is incompletely understood, and
is unclear if these lesions are developmental in nature or are
acquired after birth. Although adult DAVFs are thought to be
acquired lesions secondary to trauma or venous thrombosis
with secondary shunt formation, pediatric DAVFs are
thought to arise from different mechanisms. One theory is
that venous thrombosis occurs in utero and results in (1)
venous hypertension with opening of dormant channels
between the external carotid and venous pathways within
the dura mater or (2) local tissue hypoxia leading to stimu-
lated production of angiogenic factors and formation of new
vascular channels.77
There are only a few established genetic aberrations asso-
ciated with DAVF formation, including mutations in PTEN and
RASA1.78–80 Associated syndromes include Bannayan–Riley–
Ruvalcaba syndrome, HHTsyndrome, and craniofacial arterio-
venous metameric syndrome.27,81–83
Epidemiology and Natural History
Pediatric DAVFs are rare lesions, and there are limited data
describing their incidence. In a study from Japan, annual
detection rates based on a population-based study were
estimated to be 0.0323 per 100,000 person-years.84 DAVFs
compose approximately 5 to 10% of all pediatric intracranial
arteriovenous shunting lesions.73,77,85 The natural history of
pediatric DAVFs is also incompletely understood, but it is
believed that symptoms typically progress for untreated
lesions. A subset of these lesions can also demonstrate rapid
“runaway” angiographic and clinical progression over time,
eventually converting from a controllable lesion to an uncon-
trollable lesion.86 Rupture can lead to severe neurologic com-
promise or death. Spontaneous resolution of symptoms
associated with DAVFs has only been rarely reported.87
Clinical Presentation
Lasjaunias et al88 reported age of onset in the neonatal
period, infancy, or childhood in 27.6, 48.3, and 24.1% of
cases, respectively. Similar to VoGMs andAVMs, presentation
of these lesions depends on age, location of mass effect,
Fig. 1 Volume-staged radiosurgery followed by surgical resection for a pediatric arteriovenous malformation (AVM; SM4-Supp3). A 16-year-old
female who presented with a grand mal seizure with imaging demonstrated a right frontal AVM (A: T1 postgadolinium MR axial image).
Pretreatment angiography (C, D, lateral and PA projections) demonstrated a diffuse nidus measuring 10 6.5 6.5 cm with both deep and
superficial drainage without associated intranidal or flow-related aneurysms. The patient subsequently underwent volume-staged radiosurgery
with two separate treatments (1st: 9.7 mL treated with 17 Gy to 50% isodose line; 2nd: 11.5 mL treated with 17 Gy to 50% isodose line) which led
to a substantial decrease in the size of the AVM (B). The patient then underwent surgical resection of the lesion, with postoperative angiography
(E, F) demonstrating no residual shunting.
j
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and degree of high-flow steal. In children under the age of
1 year, clinical presentation typically includes congestive
heart failure, respiratory failure, and hydrocephalus with
associated macrocrania, compared with children over the
age of 1 year who more frequently present with a focal
neurologic deficit.77 Older children may demonstrate devel-
opmental delay and seizures. Venous congestion secondary
to thrombosis can lead to venous infarction and hemorrhage.
Rarely, thrombocytopenia may develop due to platelet con-
sumption within clots that form within vessels.
Diagnostic Imaging and Anatomic Classification
DAVFs are typically identified on MRI at first presentation,
andMR angiography and venographymay be obtained at the
same time to allow for further characterization. However,
DSA is the gold standard for diagnostic imaging of these
lesions. Dural branches of the external carotid, internal
carotid, and vertebrobasilar circulation are the arterial
feeders of these fistulas, which subsequently drain into
cortical veins and/or dural venous sinuses. DAVFs have
been categorized by two different classification systems
based on direction of venous flow and the presence of
cortical drainage.89,90 Lasjaunias et al classified pediatric
dural AVFs into three groups: dural sinus malformations,
infantile-type dural arteriovenous shunts, and adult-type
dural arteriovenous shunts.73 Dural sinus malformation
typically presents in the first few months of life and include
two subtypes: (1) shunts involving adjacent posterior
sinuses with giant pouches and slow flowmural AV shunting
and (2) shunts of the jugular bulb. A favorable prognostic sign
for dural sinus malformation is sparing of the torcula. Infan-
tile-type dural arteriovenous shunts typically present in the
first few years of life and are high flow and low pressure in
nature. The draining venous sinus is large, and there are no
venous lake or sinus malformations. Adult-type dural arte-
riovenous shunts are similar to adult DAVFs, and can develop
following venous sinus or cortical vein thrombosis or trau-
ma. These lesions are often low-flow shunts in children.
Treatment and Outcomes
The treatment of pediatric DAVFs typically involves endovas-
cular embolizationand/or surgery,with radiosurgery reserved
for cases of endovascular treatment failure. Given the young
age of many of these patients, endovascular approaches must
overcome the challenges of tortuous intracranial feeding
arteries, smaller arterial access sites (e.g., femoral artery),
and increased risks of general anesthesia particularly in neo-
nates. Some groups advocate for anticoagulation to ensure
sinus patency as venous thrombosis can result in devastating
consequences,91,92 though this approach can reduce the effi-
cacy of embolization and remains controversial. Favorable
prognostic factors in patients include localization to a unilat-
eral dural sinus, location removed from the torcula and
superior sagittal sinus, and small/low-flow shunts.
Endovascular Embolization
Endovascular embolization has been the primary treatment
for pediatric DAVFs and is typically performed through a
transarterial route, although transvenous and transumbilical
approaches have been reported as well.93,94 Transtorcular
direct puncture embolization has largely been abandoned
following thedevelopmentofhighlyflexible catheters.Reports
of staged embolization have also been described.60,95 Our
group reportedoutcomes in22patients (12males, 10 females),
of which 16 harbored single shunts and 6 harbored multiple
shunts. Complete obliterationwas achieved in 38% of patients
by the end of treatment, and 27% of the cohort died by the end
of follow-up, demonstrating lower rates of angiographic oblit-
eration and poorer clinical outcomes when compared with
their adult counterparts.77 Other groups have reported even
highermortality rates of 31 to 38%, with anatomic cure in only
a fraction of patients, especially when the posterior dural
sinuses are involved.73,76 More modern cohorts demonstrate
slightly higher rates of good recovery which may be due to
improvement in endovascular technique.81 ►Figs. 2 and 3
demonstrate case examples using endovascular embolization
to treat intracranial DAVFs.
Surgery and Radiosurgery
Surgery has been used previously and in conjunction with
endovascular embolization for DAVFs, and involves placing a
clip across the anomalous arteriovenous connection.96,97
Radiosurgery has been rarely used for these lesions in
instances of endovascular treatment failure.98 Zaidi et al
reported on outcomes in 12 patients with DAVFs or mixed
pial/dural AVFs treated in part with surgery or multimodal
treatment, with 7 cases involving surgical clipping. Complete
obliteration was seen in all cases, and one of these patients
died from acute sinus thrombosis.98
Vein of Galen Malformations
AVoGM is a congenital pial AVFandusually consists ofmultiple
arteriovenousshuntsof the choroidal arterial systemthatdrain
into a dilated median prosencephalic vein, a precursor to the
vein of Galen.99 This is distinguished from off-midline arterio-
venous malformations in this region that have an intervening
nidus with venous drainage into a dilated but already formed
vein of Galen. The age of presentation tends to be during the
neonatal or infancyperiod, typicallyat ayoungerage compared
withAVMs.Theselesionshavebeenhistoricallyassociatedwith
a poor prognosis, although contemporary embolization strate-
gies allow for successful treatment in some cases.
Etiology and Genetics
The etiology for VoGMs is incompletely understood, but is
related to abnormal embryological development of the cere-
bral vascular system. Arteriovenous shunts develop typically
between thechoroidal arteriesand themedianprosencephalic
veinbetweenweeks6and11ofembryologicaldevelopment.99
This shunting leads to progressive enlargement of the anterior
segment of the median prosencephalic vein of Markowski.
There are a fewgeneticmutations that are associatedwith
VoGM formation. RASA1 mutations, associated with CM-
AVM syndrome,100 and mutations in ENG and ACVRL1, asso-
ciated with HHTs, have been reported in some VoGMs.101,102
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Fig. 2 Endovascular embolization of an intracranial dural arteriovenous fistula (DAVF). The patient is an 8-year-old female with C1q deficiency
and lupus with an incidentally discovered torcular DAVF supplied by three branches of the left middle meningeal artery and draining intomultiple
cerebellar cortical veins (A, B: T1 postgadolinium MR axial and coronal images; C, D: PA and lateral projections on angio). She underwent
transarterial embolization with Onyx via the left middle meningeal artery (E, J) with no residual fistula seen at the end of the procedure (H, I).
Postprocedure MR imaging demonstrated Onyx within the feeding arteries (F, G).
Fig. 3 Endovascular embolization of an intracranial dural arteriovenous fistula (DAVF) in an infant. The patient is a 3-month-old male born full
term and was found to have a bruit behind the right ear. Imaging demonstrated a DAVF of the right transverse-sigmoid sinuses with supply from
the occipital artery, right neuromeningeal trunk, and right middle meningeal artery (A, B: Lateral and PA projections on angio; (C) T1
postgadolinium MR axial images). The DAVF was subsequently treated with coil embolization; angiography demonstrated no residual shunting
(D, E). Postprocedure MR imaging demonstrated coils within the anomalous connection (F).
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However, these mutations are identified only in a fraction of
these lesions.103 Recent evidence demonstrates that many
lesions are due to de novo mutations. Duran et al performed
exome sequencing of 55 VoGM probands, which revealed
enrichment of rare damaging de novo mutations in chroma-
tin-modifier genes critical for brain and vascular develop-
ment as well as ephrin signaling genes including EPHB4. The
inherited mutations showed incomplete penetrance and
variable expressivity with carriers of the mutations often
exhibiting cutaneous vascular abnormalities, consistent
with a “two-hit” geneticmechanism.104 The identifiedmuta-
tions in this study accounted for only approximately 30% of
VoGM cases, suggesting further investigation is needed to
elucidate a more complete picture of genetic driver muta-
tions for formation of these lesions.
Epidemiology
VoGMs are rare congenital vascular lesions that represent less
than 1% of all arteriovenous malformations in the cooperative
study of subarachnoid hemorrhage.105,106 However, some
historical reports suggested these lesions accounted for 30%
of all pediatric vascular lesions.107 Currently, there are no
reports detailing the prevalence or incidence of the lesions,
likelygiven their rareoccurrence.Annualdetection ratesbased
on a population-based study were estimated to be 0.0517 per
100,000 person-years.84
Clinical Presentation and Natural History
Clinical presentation for patientswithVoGMvaries significant-
ly by age. If arteriovenous shunting is a substantial fraction of
the cardiac output, it can lead to congestive heart failure and
associatedmultiorgan failure, sometimespresenting inuteroas
hydrops fetalis or in the early neonatal period. Venous conges-
tion can present with facial vein prominence, irritability,
altered mental status, hemorrhage, seizures, or acute hernia-
tion. Chronic venous ischemia leading to calcifications could
result in epilepsy. Increased intracranial pressure may present
as macrocrania if the cranial sutures have not fused, and
hydrocephalus may develop from obstruction of cerebrospinal
fluid drainage pathways. For older children, neurocognitive
impairment may be seen. In a systematic review and meta-
analysis by Brinjikji et al, congestive heart failurewas themost
frequent presenting symptom in neonates. Increased head
circumference, heart failure, and hydrocephalus were the
most common symptoms in infants. Increased head circumfer-
ence, hydrocephalus, and seizures were the most common
presenting symptom in children.108 In a cohort of 31 children
with VoGMs, Gopalan et al reported themedian age of presen-
tation to be 9.6 months (range: 1.2 months to 11 years).109
Historically, VoGMs have been associated with a high
mortality rate with worse outcomes in neonates.88,108 Yan
et al performed a meta-analysis of 31 studies including 754
patients todeterminethenatural progressionofVoGMs,witha
focus onpatientswhodied before receivingmedical attention,
patients who required emergency treatment, and patients
who developed spontaneous thrombosis. The risk of preoper-
ative sudden death in the cohort was 6%, with the rate
gradually declining with age. The majority of patients (94%)
presenting with sudden death were neonates, and the rate of
emergencyoperationsgradually increasedwithage.Theriskof
spontaneous thrombosis of the vascular lesion was 1%, and
thrombosis occurring at a younger age appeared to be associ-
ated with more favorable outcomes.110
Diagnostic Imaging and Anatomic Classification
VoGMs are typically identified on MRI at first presentation.
MR angiography may be obtained at the same time to allow
for better characterization. In younger patients, these lesions
may be picked up on ultrasonography through the anterior
fontanelle (►Fig. 4). Although DSA is the gold standard for
Fig. 4 (A, B) Fetal presentation of a vein of Galen malformation (VoGM). The patient is an infant male born at 32 weeks to a 28-year-old female
G1P0 who had a dichorionic diamniotic twin pregnancy. The VoGM was detected during fetal monitoring of the twin pregnancy with other
features including associated cardiomegaly and reversal of flow in the distal aortic arch with carotid artery steal. The patient presented shortly
after birth with high-output cardiac failure. Coronal and sagittal ultrasound images obtained on the day of birth demonstrated a large VoGM
contributing to aortic flow reversal. The patient died on the first day of life despite aggressive medical interventions.
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evaluating these lesions, some groups advocate for angiog-
raphy only if embolization is being attempted to avoid
complications associated with repeat angiograms, especially
in neonates and infants.
Arterial supply involves the choroidal arteries and very
rarely thalamoperforating arteries. The nidus of the lesion is
located in themidlineandreceivesbilateral supply. Thevenous
drainage iswithin adilatedmedianveinof theprosencephalon
without communication with the deep venous system. The
straight sinus is typically absent, and the deep venous system
has alternative drainage pathways. On imaging, lesionsmaybe
classified as mural or choroidal. The mural type consists of
the shunt ending directly within the aneurysmal wall of the
dilated median prosencephalic vein. There may be a single or
multiple fistulas, and this type of VoGM is easier to cure and
has amore favorable prognosis. The choroidal type involves an
interposed arterial network from contributions of choroidal
arteries before opening into thevenous aneurysm. Thenumer-
ous feeding arteries increase the difficulty of treatment, and
this type has a worse prognosis. In a series of 41 patients,
mural, choroidal, andmixed types of VoGMwere seen in 29.3,
26.8, and 31.7% of the cohort, respectively.111
Treatment and Outcomes
In the past, surgical resection of these lesions was attempted
but was associated with high mortality. In the current era,
treatment for VoGMs is primarily byendovascularmodalities
including both transarterial and transvenous approaches. In
an effort to assist with appropriate patient selection for
procedural intervention, a neonatal evaluation score has
been proposed to help determine if multiorgan failure pre-
cluded adequate recovery with angiographic cure of the
lesion.88
Endovascular Embolization
Embolization of VoGMs has been achieved with a variety of
agents including coil and glue embolization.88,111,112 Lasjau-
nias et al reported outcomes in 233 of a total cohort of 317
patients who were treated with transarterial approach for
endovascular embolization with glue (n-butylcyanoacrylate).
Of the 216patients treated at their institution, 23 died (10.6%),
and of the surviving patients, 20 were reported with severe
developmental delay, 30 with moderate developmental delay,
and 143 were neurologically normal.88 Death was more
frequent in the neonate population (52%),88 which has also
been reported inother studies.113,114Ourgrouphaspreviously
examined outcomes in 41 patients undergoing transarterial,
transvenous, or transtorcular (only used prior to 2000)
approaches for embolization of a VoGM. Overall, the median
numberof treatments for the cohort was 2 embolizationswith
a bimodal distribution of treatment predominantly urgently
within 10 days and electively after 1 year of age. A normal or
mildly disabled functional status was seen in 50% of cases,
survival rate was 78% by the end of follow-up, and complete
thrombosis of the VoGM was 62.5% on radiographic follow-
up.111 At our institution, worse outcomes appear associated
with choroidal angioarchitecture, perinatal presentation, and
the presence of CHF.115 In a systematic review and meta-
analysis, Brinjikji et al analyzed 27 series totaling 578 patients
who underwent endovascular treatment of VoGMs. All-cause
mortality was 14.0%, and good neurologic outcome rates were
seen in 62.0%, with neonates significantly less likely to have
good neurologic outcomes compared with infants. Treatment
indications following the Bicetre neonatal evaluation score
resulted in significantly higher rates of good neurologic
outcome.108
Stereotactic Radiosurgery
Stereotactic radiosurgery has rarely been used for the treat-
ment of these vascular lesions in cases of recurrence or
vascular anatomy precluding embolization.116,117 Payne
et al reported on the use of SRS in nine consecutive patients
with VoGMs, four of which had failed prior embolization.
Follow-up angiograms were obtained in eight of the nine
patients and demonstrated no further filling of the VoGM in
four patients, one patient with a residual fistula not included
in the initial treatment field, and two patients with marked
reduction of flow through the malformation. There were no
deaths in the cohort.117 Triffo et al reported on two cases
which responded well to SRS.116 The first case was of a
neonate who suffered multiple recurrences of a VoGM
despite transarterial and transvenous embolizations and
underwent SRS with a prescription dose of 17 Gy at the
50% isodose surface delivered to the malformation. At last
follow-up, the patient remainedwithout neurological deficit
or enlargement of the malformation. The second case was in
a 27-year-oldmalewith a choroidal-type VoGM inwhich the
anatomy of the lesion precluded embolization; so, SRSwith a
prescription dose of 18Gy at the 50% isodose surface was
used. At last follow-up, the patient had slight left-sided
dysmetria but was otherwise neurologically intact with
complete resolution of the VoGM.116
Conclusions
Brain AVMs, DAVFs, andVoGMs remain challenging lesions to
treat and can cause devastating neurologic compromise in
children. Brain AVMs may be managed with surgery, endo-
vascular embolization, stereotactic radiation, or with multi-
modal therapy. However, specific treatment regimens based
on AVM grading remains controversial, and clinical trial data
are lacking in the pediatric population. We recommend that
treatment modalities be tailored to each individual patient
based on discussion within a multidisciplinary team. Con-
trary to this, DAVFs and VoGMs can typically be managed
with endovascular approaches, although surgery and, less
frequently, radiosurgery remain alternative treatment
options for cases refractory to embolization. Although
many single-center reports have provided insights into the
clinical management of these lesions, there is a need for
multicenter collaboration to accumulate large cohorts of
patients to examine somatic mutations associated with a
predisposition for lesion formation. By identifying key aber-
rant molecular pathways associatedwith these lesions, novel
treatment strategies may be developed to hinder the forma-
tion and progression of these lesions.
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